Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Guinan

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Journal of Religion and Health|May 6, 2003
Toward a more natural medicinePatrick Guinan
Journal of Religion and Health|May 6, 2003
Bioterrorism, embryonic stem cells, and FrankensteinPatrick Guinan
In Vivo (Athens, Greece)|July 30, 2010
Bispecific antisense oligonucleotides have activity comparable to monospecifics in inhibiting expression of BCL-2 in LNCaP cellsMarvin Rubenstein, Patrick Guinan
The Linacre Quarterly|August 8, 2018
What Do Medical Students Think about Medical Ethics? UIC-COM Student Medical Ethics QuestionnaireBrian Bamberger, Patrick Guinan
Medical Oncology (Northwood, London, England)|September 13, 2007
Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumorsMarvin Rubenstein, Paulus Tsui, Patrick Guinan
Medical Oncology (Northwood, London, England)|November 1, 2007
Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity toward proteins associated with autocrine regulated growth and BCL-2Marvin Rubenstein, Paulus Tsui, Patrick Guinan
Medical Oncology (Northwood, London, England)|October 6, 2007
Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumorsMarvin Rubenstein, Paulus Tsui, Patrick Guinan
In Vivo (Athens, Greece)|July 8, 2005
siRNA is not more effective than a first generation antisense oligonucleotide when directed against EGFR in the treatment of PC-3 prostate cancerPaulus Tsui, Marvin Rubenstein, Patrick Guinan
Medical Hypotheses|July 19, 2005
Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumorsMarvin Rubenstein, Paulus Tsui, Patrick Guinan
Journal of Drug Targeting|June 2, 2007
Targeting of biotinylated oligonucleotides to prostate tumors with antibody-based delivery vehiclesYelena Mirochnik, Marvin Rubenstein, Patrick Guinan
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Journal of Religion and Health|May 6, 2003
Toward a more natural medicinePatrick Guinan
Journal of Religion and Health|May 6, 2003
Bioterrorism, embryonic stem cells, and FrankensteinPatrick Guinan
In Vivo (Athens, Greece)|July 30, 2010
Bispecific antisense oligonucleotides have activity comparable to monospecifics in inhibiting expression of BCL-2 in LNCaP cellsMarvin Rubenstein, Patrick Guinan
The Linacre Quarterly|August 8, 2018
What Do Medical Students Think about Medical Ethics? UIC-COM Student Medical Ethics QuestionnaireBrian Bamberger, Patrick Guinan
Medical Oncology (Northwood, London, England)|September 13, 2007
Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumorsMarvin Rubenstein, Paulus Tsui, Patrick Guinan
Medical Oncology (Northwood, London, England)|November 1, 2007
Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity toward proteins associated with autocrine regulated growth and BCL-2Marvin Rubenstein, Paulus Tsui, Patrick Guinan
Medical Oncology (Northwood, London, England)|October 6, 2007
Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumorsMarvin Rubenstein, Paulus Tsui, Patrick Guinan
In Vivo (Athens, Greece)|July 8, 2005
siRNA is not more effective than a first generation antisense oligonucleotide when directed against EGFR in the treatment of PC-3 prostate cancerPaulus Tsui, Marvin Rubenstein, Patrick Guinan
Medical Hypotheses|July 19, 2005
Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumorsMarvin Rubenstein, Paulus Tsui, Patrick Guinan
Journal of Drug Targeting|June 2, 2007
Targeting of biotinylated oligonucleotides to prostate tumors with antibody-based delivery vehiclesYelena Mirochnik, Marvin Rubenstein, Patrick Guinan
Pageof 4